Encouraging Clinical Results with In Situ Conversion Therapy NXL-004 for Malignant Glioma Reported
In the patient receiving intratumoral injection, a clear therapeutic response was observed, with target lesion shrinkage exceeding 90%. In one patient treated with tumor resection followed by intracavitary injection of NXL-004, postoperative imaging demonstrated progressive tumor reduction leading to complete radiographic disappearance, achieving a complete response (CR). The results demonstrate that NXL-004 exhibits both a favorable safety profile and promising clinical efficacy, validating the feasibility and therapeutic potential of in situ conversion therapy in the treatment of glioma.
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo